D027 OA 1 Actual Exam V1 | D027 Advanced Pathopharmacology
(D027 OA 1) | Western Governors University PDF
1. A patient is prescribed a drug that is a known inhibitor of the CYP3A4 enzyme. What is the
most likely result when this patient also takes another drug that is a substrate for the same
enzyme?
A. The substrate drug’s concentration will increase, potentially leading to toxicity.
B. The substrate drug’s metabolism will increase, leading to subtherapeutic levels.
C. The inhibitor drug will become less effective over time due to induction.
D. There will be no clinical impact as enzymes are not saturated.
Answer: A
Rationale: Inhibitors of the CYP450 system slow down the metabolism of substrate drugs.
This causes the substrate drug to accumulate in the bloodstream at higher concentrations
than intended. As a result, the risk for adverse drug reactions and toxicity increases
significantly, requiring dose adjustments or careful monitoring.
2. Which pharmacokinetic parameter best describes the theoretical space required to contain
the total amount of a drug at the same concentration as in the plasma?
A. Bioavailability (F)
B. Clearance (Cl)
C. Volume of Distribution (Vd)
D. Half-life (t1/2)
Answer: C
Rationale: Volume of distribution is a theoretical value that helps clinicians understand
how a drug is distributed throughout the body. A high Vd suggests that the drug is highly
lipid-soluble and is distributed widely into tissues. Conversely, a low Vd indicates that the
drug primarily remains within the vascular space or is highly protein-bound.
3. A partial agonist is characterized by which of the following properties when compared to a
full agonist?
A. It has lower intrinsic activity and cannot reach maximal effect.
B. It produces a maximal response at a lower dose.
C. It has higher efficacy regardless of concentration.
D. It has higher affinity but lower potency.
,Answer: A
Rationale: Partial agonists bind to the same receptor site as full agonists but elicit a
smaller maximal response. Even at high concentrations where all receptors are occupied,
the partial agonist will not produce the same biological effect as a full agonist. This
property is known as having lower intrinsic activity, which can sometimes make these
drugs act as functional antagonists in the presence of full agonists.
4. When a drug undergoes extensive first-pass metabolism, what is the primary consequence
for oral administration?
A. The drug will have a very high bioavailability.
B. The drug will reach the systemic circulation faster than IV administration.
C. The drug is excreted unchanged in the urine without entering the blood.
D. A significant portion of the drug is metabolized by the liver before reaching systemic
circulation.
Answer: D
Rationale: First-pass metabolism occurs when a drug is absorbed from the gastrointestinal
tract and enters the portal vein to the liver. The liver may metabolize a large percentage of
the drug before it can reach the heart and the rest of the body. This reduces the total
bioavailability of the oral dose, often requiring much higher oral doses compared to
intravenous doses.
5. Selectivity for Beta-2 receptors in bronchodilators like Albuterol is important because it
minimizes which adverse effect?
A. Hypoglycemia
B. Urinary retention
C. Tachycardia and palpitations
D. Excessive salivation
Answer: C
Rationale: Beta-2 receptors are primarily located in the lungs, while Beta-1 receptors are
located in the heart. While selectivity is not absolute, Beta-2 selective agonists are designed
to target the lungs to cause bronchodilation. If the drug were to significantly stimulate
Beta-1 receptors, it would cause increased heart rate and myocardial oxygen demand.
6. Why is the incidence of dry cough higher in patients taking ACE inhibitors compared to
those taking Angiotensin II Receptor Blockers (ARBs)?
A. ARBs directly stimulate the cough center in the brain.
B. ACE inhibitors cause an accumulation of bradykinin in the lungs.
, C. ACE inhibitors cause systemic alkalosis which irritates the airway.
D. ARBs inhibit the breakdown of prostaglandins more effectively.
Answer: B
Rationale: The Angiotensin-Converting Enzyme (ACE) is also responsible for the
degradation of bradykinin, an inflammatory mediator. When ACE is inhibited, bradykinin
levels rise in the pulmonary system, leading to the characteristic dry, hacking cough seen in
some patients. ARBs do not affect ACE directly and therefore do not cause this bradykinin
buildup, making them a suitable alternative for patients who cannot tolerate the cough.
7. For a patient with a declining Glomerular Filtration Rate (GFR), what is the most
appropriate action for a drug primarily eliminated by renal excretion?
A. Reduce the dose or increase the dosing interval.
B. Decrease the dosing interval to ensure steady state.
C. Switch to a drug with higher protein binding to prevent filtration.
D. Increase the dose to compensate for poor filtration.
Answer: A
Rationale: Reduced renal function means the body is less efficient at removing drugs
excreted through the kidneys. If the dose is not adjusted downward, the drug will
accumulate to toxic levels in the plasma. Clinicians must use GFR or Creatinine Clearance to
calculate the appropriate renal dose adjustment for such medications.
8. How many half-lives does it typically take for a drug to reach a steady-state concentration
in the plasma?
A. 1 to 2 half-lives
B. 4 to 5 half-lives
C. 10 to 12 half-lives
D. Steady state is reached after the first dose.
Answer: B
Rationale: Steady state is the condition where the rate of drug administration equals the
rate of drug elimination. Mathematically, it takes approximately four to five half-lives of
consistent dosing to reach this equilibrium. This principle is crucial when determining
when to measure therapeutic drug levels to assess the effectiveness of a chronic regimen.
9. Drug A requires a dose of 10mg to achieve a 50% maximal effect, while Drug B requires
100mg for the same effect. Both drugs can reach the same maximal effect. Which statement
is true?
A. Drug A is a partial agonist and Drug B is a full agonist.
(D027 OA 1) | Western Governors University PDF
1. A patient is prescribed a drug that is a known inhibitor of the CYP3A4 enzyme. What is the
most likely result when this patient also takes another drug that is a substrate for the same
enzyme?
A. The substrate drug’s concentration will increase, potentially leading to toxicity.
B. The substrate drug’s metabolism will increase, leading to subtherapeutic levels.
C. The inhibitor drug will become less effective over time due to induction.
D. There will be no clinical impact as enzymes are not saturated.
Answer: A
Rationale: Inhibitors of the CYP450 system slow down the metabolism of substrate drugs.
This causes the substrate drug to accumulate in the bloodstream at higher concentrations
than intended. As a result, the risk for adverse drug reactions and toxicity increases
significantly, requiring dose adjustments or careful monitoring.
2. Which pharmacokinetic parameter best describes the theoretical space required to contain
the total amount of a drug at the same concentration as in the plasma?
A. Bioavailability (F)
B. Clearance (Cl)
C. Volume of Distribution (Vd)
D. Half-life (t1/2)
Answer: C
Rationale: Volume of distribution is a theoretical value that helps clinicians understand
how a drug is distributed throughout the body. A high Vd suggests that the drug is highly
lipid-soluble and is distributed widely into tissues. Conversely, a low Vd indicates that the
drug primarily remains within the vascular space or is highly protein-bound.
3. A partial agonist is characterized by which of the following properties when compared to a
full agonist?
A. It has lower intrinsic activity and cannot reach maximal effect.
B. It produces a maximal response at a lower dose.
C. It has higher efficacy regardless of concentration.
D. It has higher affinity but lower potency.
,Answer: A
Rationale: Partial agonists bind to the same receptor site as full agonists but elicit a
smaller maximal response. Even at high concentrations where all receptors are occupied,
the partial agonist will not produce the same biological effect as a full agonist. This
property is known as having lower intrinsic activity, which can sometimes make these
drugs act as functional antagonists in the presence of full agonists.
4. When a drug undergoes extensive first-pass metabolism, what is the primary consequence
for oral administration?
A. The drug will have a very high bioavailability.
B. The drug will reach the systemic circulation faster than IV administration.
C. The drug is excreted unchanged in the urine without entering the blood.
D. A significant portion of the drug is metabolized by the liver before reaching systemic
circulation.
Answer: D
Rationale: First-pass metabolism occurs when a drug is absorbed from the gastrointestinal
tract and enters the portal vein to the liver. The liver may metabolize a large percentage of
the drug before it can reach the heart and the rest of the body. This reduces the total
bioavailability of the oral dose, often requiring much higher oral doses compared to
intravenous doses.
5. Selectivity for Beta-2 receptors in bronchodilators like Albuterol is important because it
minimizes which adverse effect?
A. Hypoglycemia
B. Urinary retention
C. Tachycardia and palpitations
D. Excessive salivation
Answer: C
Rationale: Beta-2 receptors are primarily located in the lungs, while Beta-1 receptors are
located in the heart. While selectivity is not absolute, Beta-2 selective agonists are designed
to target the lungs to cause bronchodilation. If the drug were to significantly stimulate
Beta-1 receptors, it would cause increased heart rate and myocardial oxygen demand.
6. Why is the incidence of dry cough higher in patients taking ACE inhibitors compared to
those taking Angiotensin II Receptor Blockers (ARBs)?
A. ARBs directly stimulate the cough center in the brain.
B. ACE inhibitors cause an accumulation of bradykinin in the lungs.
, C. ACE inhibitors cause systemic alkalosis which irritates the airway.
D. ARBs inhibit the breakdown of prostaglandins more effectively.
Answer: B
Rationale: The Angiotensin-Converting Enzyme (ACE) is also responsible for the
degradation of bradykinin, an inflammatory mediator. When ACE is inhibited, bradykinin
levels rise in the pulmonary system, leading to the characteristic dry, hacking cough seen in
some patients. ARBs do not affect ACE directly and therefore do not cause this bradykinin
buildup, making them a suitable alternative for patients who cannot tolerate the cough.
7. For a patient with a declining Glomerular Filtration Rate (GFR), what is the most
appropriate action for a drug primarily eliminated by renal excretion?
A. Reduce the dose or increase the dosing interval.
B. Decrease the dosing interval to ensure steady state.
C. Switch to a drug with higher protein binding to prevent filtration.
D. Increase the dose to compensate for poor filtration.
Answer: A
Rationale: Reduced renal function means the body is less efficient at removing drugs
excreted through the kidneys. If the dose is not adjusted downward, the drug will
accumulate to toxic levels in the plasma. Clinicians must use GFR or Creatinine Clearance to
calculate the appropriate renal dose adjustment for such medications.
8. How many half-lives does it typically take for a drug to reach a steady-state concentration
in the plasma?
A. 1 to 2 half-lives
B. 4 to 5 half-lives
C. 10 to 12 half-lives
D. Steady state is reached after the first dose.
Answer: B
Rationale: Steady state is the condition where the rate of drug administration equals the
rate of drug elimination. Mathematically, it takes approximately four to five half-lives of
consistent dosing to reach this equilibrium. This principle is crucial when determining
when to measure therapeutic drug levels to assess the effectiveness of a chronic regimen.
9. Drug A requires a dose of 10mg to achieve a 50% maximal effect, while Drug B requires
100mg for the same effect. Both drugs can reach the same maximal effect. Which statement
is true?
A. Drug A is a partial agonist and Drug B is a full agonist.
